Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | See Remarks | September 10, 2026 | September 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date September 10, 2026 · Filed September 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 97,475 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 14,754 · Balance 97,475 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2: The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026. |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 35,475 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Sale · Disposed 62,000 · Balance 35,475 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
F2: The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 12, 2026 00:14 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | SaleCommon Stock, par value $0.00001 per share | 62,000 | $5.18 | $321,178.60 |
DisclosureSEC source: 0001193125-26-389564 · ownership.xml · nonDerivative · entry 2 Sun Nelson · CIK 0002045377 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. Read SEC document |
| September 10, 2026 Filed Sep 12, 2026 00:14 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | SaleCommon Stock, par value $0.00001 per share | 14,754 | $5.00 | $73,778.85 |
DisclosureSEC source: 0001193125-26-389564 · ownership.xml · nonDerivative · entry 1 Sun Nelson · CIK 0002045377 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F2 · price: The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:00 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock option (right to buy) · Derivative | 70,549 | $0.00 Strike: $13.48 | $0.00 |
DisclosureSEC source: 0001193125-26-047317 · ownership.xml · derivative · entry 1 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,549 Underlying: Common Stock · 70,549 shares Expires 2036-02-09 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 20:30 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | PurchaseCommon Stock | 3,000 | $14.40 | $43,200.00 |
DisclosureSEC source: 0001193125-25-318070 · ownership.xml · nonDerivative · entry 1 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,484 Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 17:36 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | PurchaseCommon Stock | 6,000 | $8.07 | $48,439.80 |
DisclosureSEC source: 0001193125-25-200226 · ownership.xml · nonDerivative · entry 1 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,484 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.00 to $8.20 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 209,826 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086143 · ownership.xml · derivative · entry 1 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,826 Underlying: Common Stock · 209,826 shares Expires 2035-06-11 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 11, 2026, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 16:30 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionSeries C Convertible Preferred Stock · Derivative | 59,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023243 · ownership.xml · derivative · entry 3 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 16:30 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | PurchaseCommon Stock | 10,000 | $16.00 | $160,000.00 |
DisclosureSEC source: 0000950170-25-023243 · ownership.xml · nonDerivative · entry 2 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,484 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 16:30 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionCommon Stock | 7,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023243 · ownership.xml · nonDerivative · entry 1 Sun Nelson · CIK 0002045377 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.